Erythrocyte calpain activity and left ventricular mass in essential hypertension

Journal of Hypertension

Volumn 15, Issue 12, 1997, Pages 1775-1778

  Stella, Paola ^a   Soldati, Laura ^a   Ciurlino, Daniele ^a   Vezzoli, Giuseppe ^a   Cusi, Daniele ^a   Bianchi, Giuseppe ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Calpain; Calpastatin; Cardiomyocytes; Erythrocytes; Hypertension; Left ventricular hypertrophy; Left ventricular mass index

Indexed keywords

CALPAIN; CALPASTATIN;

ADULT; CONFERENCE PAPER; DIASTOLIC BLOOD PRESSURE; ERYTHROCYTE; ESSENTIAL HYPERTENSION; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HUMAN; M MODE ECHOCARDIOGRAPHY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE;

EID: 0031474311     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/00004872-199715120-00088     Document Type: Article

References (26)

1. Pontremoli S, Melloni E, Sparatore B, Salamino F, Pontremoli R, Tizianello A, et al.: Erythrocyte deficiency in calpain inhibitor activity in essential hypertension. Hypertension 1988, 12:474-478.
2. Pontremoli S, Melloni E, Salamino F, Sparatore B, Viotti P, Micheletti M, et al.: Decreased level of calpain inhibitor activity in kidney from Milan hypertensive rats. Biochem Biophys Res Commun 1987, 145:1287-1294.
3. Pontremoli S, Melloni E, Sparatore B, Salamino F, Pontremoli R, Tizianello A: Increased phosphorylation in red cell membranes of subjects affected by essential hypertension. Biochem Biophys Res Commun 1987, 145:1329-1334.
4. Kannel WB, Cobb J: Left ventricular hypertrophy and mortality results from the Framingham study. Cardiology 1992, 81:291-298.
5. Wong KK, Summers KM, Burstow DJ, West MJ: Genetic variants of proteins from the renin angiotensin system are associated with pressure load cardiac hypertrophy. Clin Exp Pharmacol Physiol 1996, 23:587-590.
6. Gharavi AG, Lipkowitz MS, Diamond JA, Jhang JS, Phillips RA: Deletion polymorphism of the angiotensin-converting enzyme gene is independently associated with left ventricular mass and geometric remodeling in systemic hypertension. Am J Cardiol 1996, 77:1315-1319.
7. Donohue TJ, Dworkin LD, Lango MN, Fliegner K, Lango RP, Benstein JA, et al.: Induction of myocardial insulin-like growth factor-I gene expression in left ventricular hypertrophy. Circulation 1994, 8 (suppl 9):799-809.
8. Calderone A, Takahashi N, Izzo NJ Jr, Thaik CM, Colucci WS: Pressure- and volume-induced left ventricular hypertrophies are associated with distinct myocyte phenotypes and differential of peptide growth factors mRNAs. Circulation 1995, 92:2385-2390.
9. Cicilini MA, Resende MM, Bissoli NS, Vasquez EC, Cabral AM: Calpain activity of hypertrophic hearts from hypertensive rats. Braz J Med Biol Res 1995, 28:621-625.
10. Pontremoli S, Melloni E, Salamino F, Sparatore B, Viotti P, Michetti M, et al.: Decreased level of calpain inhibitor activity in red blood cells from Milan hypertensive rats. Biochem Biophys Res Commun 1986, 138:1370-1377.
11. Sahn DJ, De Maria A, Kisslo J, Weyman A: The Committee on M-mode Standardization of the American Society of Echocardiography. Recommendations regarding quantitation in M-mode echocardiography: result of a survey of echocardiographic measurements. Circulation 1978, 58:1072-1083.
12. Devereux RB, Reichek N: Echocardiographic determination of left ventricular mass in man. Circulation 1977, 55:613-618.
13. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJG, Campo E, Sachs I, Reichek N: Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986, 57:450-458.
14. Schmieder RE, Martus P, Klingbeil A: Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies. JAMA 1996, 275:1507-1513.
15. O'Brien E, Coyle D: Ambulatory blood pressure measurement and the occurrence of hypertensive organ involvement. Neth J Med 1995, 47:145-151.
16. Lemne C, Lindvall K, Georgiades A, Fredrikson M, de Faire U: Structural cardiac changes in relation to 24-h ambulatory blood pressure levels in borderline hypertension. J Intern Med 1995, 238:49-57.
17. Saido TC, Sorimachi H, Suzuki K: Calpain: new perspectives in molecular diversity and physiological-pathological involvement. FASEB J 1994, 8:814-822.
18. Croall DE, Demartino GN: Calcium-activated neutral protease (calpain) system: structure, function, and regulation. Physiol Rev 1991, 71:813-847.
19. Johnson P, Hammer JL: Cardiac and skeletal muscle enzyme levels in hypertensive and ageing rats. Comp Biochem Physiol 1993, 104b:63-67.
20. Soldati L, Alberoni M, Bianchi G, Canal N, Franceschi M: Erythrocytic calpain-calpastatin system in Alzheimer's disease. Aging 1996, 8:106-108.
21. ++ at rest and after cholinergic stimulus is increased in cultured muscle cells from Duchenne muscular dystrophy patients. Neurology 1988, 38:476-480.
22. Wang KKW, Yuen PW: Calpain inhibition: an overview of its therapeutic potential. Trends Pharmacol Sci 1994, 15:412-419.
23. Cohen S, Ushiro H, Stoscheck C, Chinkers M: A native 170,000 epidermal growth factors receptor-kinase complex from shed plasma membrane vesicles. J Biol Chem 1982, 257:1523-1531.
24. Pant HC, Virmani M, Gallant PE: Calcium-induced proteolysis of spectrin and band 3 protein rat erythrocytes membranes. Biochem Biophys Res Commun 1983, 117:372-377.
25. Nishizuka Y: The role of protein kinase C in cell surface signal transduction and tumor production. Nature 1984, 308:693-698.
26. Soldati LP, Barber BR, Salardi S, Molinari I, Bianchi G: A new rat model for studying the calpain-calpastatin system. Lab Anim 1995, 29: 420-426.